James M. Burke
Plus aucun poste en cours
Profil
James M.
Burke, former Associate Director-Clinical Research at Cell Genesys, Inc., former Director-Cancer Research at Billings Clinic, former Vice President-Clinical Research at SillaJen Biotherapeutics, Inc., and former Chief Medical Officer at CG Oncology, Inc. He obtained his undergraduate degree from the University of California San Diego and his doctorate degree from Georgetown University.
Anciens postes connus de James M. Burke
| Sociétés | Poste | Fin |
|---|---|---|
| CG ONCOLOGY, INC. | Directeur Technique/Scientifique/R&D | - |
Billings Clinic
 Billings Clinic Hospital/Nursing ManagementHealth Services Billings Clinic provides health care services. It offers audiology, immunology, assited living, clinical services, emergency services, eye center, obstetrics and gynecology, oncology, ophthalmology, occupational medicine, and neurology. The company was founded in 1911 and is headquartered in Billings, MT. | Corporate Officer/Principal | - |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | - |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de James M. Burke
| Georgetown University | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CG ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Billings Clinic
Billings Clinic Hospital/Nursing ManagementHealth Services Billings Clinic provides health care services. It offers audiology, immunology, assited living, clinical services, emergency services, eye center, obstetrics and gynecology, oncology, ophthalmology, occupational medicine, and neurology. The company was founded in 1911 and is headquartered in Billings, MT. | Health Services |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
